Scribe Therapeutics Initiates Phase 1 Clinical Trial of STX-1150
Scribe Therapeutics launched a first-in-human trial for its LDL-C lowering therapy and secured substantial grant funding, while reporting a strong balance sheet of over $180 million.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day